Source link : https://www.newshealth.biz/health-news/topical-jak-inhibitor-provides-sustained-control-of-hs/
AMSTERDAM — Following the report of results from a randomized trial in which a topically applied J inhibitor (JAKi) was highly active in patients with mild to moderate hidradenitis suppurativa (HS), an open-label extension showed that 16 more weeks of treatment on as-needed basis provided complete or near complete clearance of lesions in up to […]
Author : News Health
Publish date : 2024-10-03 12:42:54
Copyright for syndicated content belongs to the linked Source.
inHealth